Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Consultee and commentator comments on the ACD
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: AntiCoagulation Europe
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Bayer
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Commissioning Support Appraisal Service
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Department of Health
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Leo Pharma
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: NHS North of Tyneside
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Pfizer
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Royal College of Nursing
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Royal College of Physicians endorse the response by Royal College of Pathologists and British Society for Haematology
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: The Vascular society
This page was last updated: 31 May 2012